142 related articles for article (PubMed ID: 23064957)
1. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Ott PA; Chang J; Madden K; Kannan R; Muren C; Escano C; Cheng X; Shao Y; Mendoza S; Gandhi A; Liebes L; Pavlick AC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):183-91. PubMed ID: 23064957
[TBL] [Abstract][Full Text] [Related]
2. Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
Bedikian AY; Garbe C; Conry R; Lebbe C; Grob JJ;
Melanoma Res; 2014 Jun; 24(3):237-43. PubMed ID: 24667300
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Alrwas A; Papadopoulos NE; Cain S; Patel SP; Kim KB; Deburr TL; Bassett R; Hwu WJ; Bedikian AY; Davies MA; Woodman SE; Hwu P
Melanoma Res; 2014 Aug; 24(4):342-8. PubMed ID: 24743052
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Movva S; Verschraegen CF; Rabinowitz I; Mangalik A; Parks V; Lee FC
Melanoma Res; 2011 Feb; 21(1):76-9. PubMed ID: 21169871
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1).
Kottschade LA; Suman VJ; Amatruda T; McWilliams RR; Mattar BI; Nikcevich DA; Behrens R; Fitch TR; Jaslowski AJ; Markovic SN
Cancer; 2011 Apr; 117(8):1704-10. PubMed ID: 21472717
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Kottschade LA; Suman VJ; Perez DG; McWilliams RR; Kaur JS; Amatruda TT; Geoffroy FJ; Gross HM; Cohen PA; Jaslowski AJ; Kosel ML; Markovic SN
Cancer; 2013 Feb; 119(3):586-92. PubMed ID: 22915053
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Spitler LE; Boasberg P; O'Day S; Hamid O; Cruickshank S; Mesko S; Weber RW
Am J Clin Oncol; 2015 Feb; 38(1):61-7. PubMed ID: 25616203
[TBL] [Abstract][Full Text] [Related]
12. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
15. Oblimersen in the treatment of metastatic melanoma.
Tarhini AA; Kirkwood JM
Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
17. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Kim KB; Hwu WJ; Papadopoulos NE; Bedikian AY; Camacho LH; Ng C; Hernandez IM; Frost AM; Jack MA; Hwu P
Cancer Chemother Pharmacol; 2009 Jun; 64(1):161-7. PubMed ID: 19002462
[TBL] [Abstract][Full Text] [Related]
19. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Yoon C; Papadopoulos NE; Camacho LH; McIntyre S; Alvarado GC; Bedikian AY; Hwu P; Kim KB
Melanoma Res; 2010 Feb; 20(1):43-7. PubMed ID: 19952963
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
